long-acting oxyntomodulin derivative

The long-acting oxyntomodulin derivative (specifically identified as MK-1462 or peptide 12) is a protease-resistant, balanced dual agonist of the glucagon-like peptide-1 receptor (GLP1R) and the glucagon receptor (GCGR). Developed by Merck in collaboration with IRBM and Indiana University, this synthetic peptide is designed to mimic the endogenous gut hormone oxyntomodulin but with a significantly extended half-life. By simultaneously activating GLP1R and GCGR, it combines the appetite-suppressing and insulinotropic effects of GLP-1 with the energy expenditure-promoting and lipolytic effects of glucagon. Preclinical studies in obese rhesus monkeys demonstrated superior body weight reduction and improved glycemic control compared to selective GLP1R agonists like liraglutide. MK-1462 is under early clinical development for the treatment of obesity and type 2 diabetes.

Other names

balanced dual agonist 12peptide 12peptide12peptide-12protease-resistant long-acting OXM derivative